Brentuximab vedotin compared to historical controls for severe skin involvement in cutaneous systemic sclerosis
Rheumatology (Oxford)
.
2024 Aug 27:keae460.
doi: 10.1093/rheumatology/keae460.
Online ahead of print.
Authors
Andreu Fernández-Codina
1
2
3
,
Tatiana Nevskaya
1
,
Murray Baron
4
,
C Thomas Appleton
1
,
Matthew J Cecchini
5
,
Amanda Philip
1
,
Maha El-Shimy
1
,
Louise Vanderhoek
1
,
Iago Pinal-Fernández
6
,
Janet E Pope
1
Affiliations
1
Division of Rheumatology, Western University, London, Ontario, Canada.
2
Division of General Internal Medicine-Windsor Campus, Western University, London, Ontario, Canada.
3
Division of Rheumatology, Rheumatology Research Group, Vall d'Hebron University Hospital, Barcelona, Spain.
4
Division of Rheumatology, Jewish General Hospital, McGill University, Montreal, Quebec, Canada.
5
Division of Pathology, Western University, London, Ontario, Canada.
6
Muscle Unit, National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, Maryland, USA.
PMID:
39189988
DOI:
10.1093/rheumatology/keae460
No abstract available
Keywords:
Systemic sclerosis; biologic; brentuximab; skin; treatment.